Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

March 24, 2025

Jill Gilbert, MD, discusses professional strategy techniques that she has found useful through incredibly challenging times.

March 18, 2025

P-BCMA-ALLO1 displayed high response rates and compelling safety in a heavily pretreated population of patients with relapsed/refractory multiple myeloma.

February 27, 2025

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

February 27, 2025

Step-up dosing with etentamig produced responses and low rates of CRS in relapsed/refractory multiple myeloma.

February 20, 2025

Networking is an underutilized skill that requires practice but can have a high impact on shaping your career path.

January 11, 2025

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

December 06, 2024

Drs Dhakal and Baljevic discuss first- and subsequent-line treatment options for patients with multiple myeloma.

November 22, 2024

Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.

October 18, 2024

Alan Tan, MD, discusses the nuances of navigating combination regimens for patients with advanced renal cell carcinoma.

October 18, 2024

Jill Gilbert, MD, highlights a recent landmark decision by the FDA concerning trial design moving forward for cancer drugs.

September 30, 2024

Cathy Eng, MD, FACP, FASCO, discusses unmet needs within the metastatic colorectal cancer treatment paradigm.

August 15, 2024

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

July 23, 2024

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.

July 21, 2024

Brian Rini, MD, details recent data in renal cell carcinoma surrounding the utility of KIM-1 as a potential biomarker and next steps for KIM-1 research.

July 09, 2024

Mary Philip, MD, PhD, discusses research on the key transcriptional and epigenetic programs that regulate CD8 T cell fate decisions in cancer models.

May 31, 2024

Christine M. Lovly, MD, PhD, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

May 28, 2024

Muhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.

May 28, 2024

Muhamed Baljevic, MD, FACP, discusses the investigation of frontline quadruplet therapies in transplant-ineligible multiple myeloma.

May 25, 2024

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.

May 24, 2024

Katie S. Gatwood, PharmD, BCOP, explains next steps with novel agents in the hematologic oncology field that have the potential to change practice.